Prediction of residual metabolic activity after treatment in NSCLC patients

Acta Oncologica

Volumn 49, Issue 7, 2010, Pages 1033-1039

  Velazquez, Emmanuel Rios ^a   Aerts, Hugo J W L ^a   Oberije, Cary ^a   De Ruysscher, Dirk ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 77956567120     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.498441     Document Type: Article

References (35)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781
2. Brawner EJ, Patrick Nana-Sinkam S, Jett JR. Lung cancer screening in 2008: A review and update. Respir Med CME 2008;1:2-9.
3. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines, 2nd ed. Chest 2007;132:S234-S42.
4. Le Chevalier T, Arriagada R, Quoix E, Ruffi e P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423
5. Florin Sirz é n EK, Sörenson S, Cavallin-St å hl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003;42:493-515.
6. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradio-therapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004;46:87-98.
7. Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386-392
8. Aerts HJ, Bosmans G, van Baardwijk AA, Dekker AL, Oellers MC, Lambin P, et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: A prospective study. Int J Radiat Oncol Biol Phys 2008;71: 1402-1407
9. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 2007;48 (Suppl 1):S36-S44.
10. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005;49:95-108.
11. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-8370
12. van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010;28:1380-1386
13. Steel G. Basic clinical radiobiology, 3rd ed. London: Hodder Arnold Publications; 2002.
14. Fung GM, Mangasarian OL. Multicategory proximal support vector machine classifiers. Mach Learn 2005;59:77-97.
15. Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomo graphy (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008;62:55-61.
16. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-9; Discussion 1909.
17. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000; 27:861-866
18. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998;9:1193-1198
19. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002;122:1037-1057
20. Dehing-Oberije C, De Ruysscher D, van Der Weide H, Hochstenbag M, Bootsma G, Geraedts W, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-1044
21. Solan MJ, Werner-Wasik M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 2003;21:64-73.
22. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan K P. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 2010;68:398-402.
23. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: Analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005;127:768-777
24. Ball D, Smith J, Wirth A, Mac Manus M. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002;54:1007-1013
25. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fluorine-18 fluoro-deoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-1464
26. Forssell-Aronsson E, Kjell é n E, Mattsson S, Hellström M, Swedish Cancer Society Investigation Group T. Medical imaging for improved tumour characterization, delineation and treatment Verification. Acta Oncol 2002;41:604-614
27. Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324-333
28. Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiother-apy. Int J Radiat Oncol Biol Phys 2009;74:355-362
29. Saunders M, Dische S, Barrett A, Harvey A, Griffi ths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-148
30. Henning Willers FW, Bünemann H, Heilmann H-P. High-dose radiation therapy alone for inoperable non-small cell lung cancer: Experience with prolonged overall treatment times. Acta Oncol 1998;37:101-105
31. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-792
32. Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, et al. 4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index. Lancet Oncol 2006;7:829-836
33. Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Tho-rac Oncol 2007;2(Suppl 2):S68-S76.
34. Naqa IE, Deasy JO, Mu Y, Huang E, Hope AJ, Lindsay PE, et al. Datamining approaches for modeling tumor control probability. Acta Oncol Epub 2010 Mar 2.
35. Encan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol 1990;29:151-154